{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:06:06Z","timestamp":1786975566264,"version":"build-2736575974"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.1001\/jamacardio.2019.1510","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T11:33:35Z","timestamp":1559129615000},"page":"680","source":"Crossref","is-referenced-by-count":14,"title":["P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes"],"prefix":"10.1001","volume":"4","author":[{"given":"Thomas J.","family":"Povsic","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Magnus","family":"Ohman","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Roe","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"White","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank W.","family":"Rockhold","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, ACTION Study Group, Institut de Cardiologie, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"Cornel","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Noordwest Ziekenhuisgroep, Alkmaar and Dutch Network for Cardiovascular Research, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose C.","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Insituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"DHU FIRE, Universit\u00e9 Paris-Diderot, AP-HP and Inserm U-1148, Paris, France"},{"name":"National Heart and Lung Institute Royal Brompton Hospital, Imperial College, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"James","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Bode","sequence":"additional","affiliation":[{"name":"University of Freiburg, Faculty of Medicine, Internal Medicine III, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Welsh","sequence":"additional","affiliation":[{"name":"Mazankowski Alberta Heart Institute and University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexei N.","family":"Plotnikov","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, Raritan, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardi","family":"Mundl","sequence":"additional","affiliation":[{"name":"Bayer AG, Wuppertal, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[{"name":"PERFUSE Study Group, Beth Israel Deaconess Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"hbr190009r1","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1124\/dmd.109.028498","article-title":"A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.","volume":"37","author":"Hagihara","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"hbr190009r2","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ahj.2010.12.011","article-title":"The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.","volume":"161","author":"Gurbel","year":"2011","journal-title":"Am Heart J"},{"issue":"8","key":"hbr190009r3","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jacc.2015.12.036","article-title":"Impact of CYP2C19 metabolizer status on patients with ACS treated with prasugrel versus clopidogrel.","volume":"67","author":"Doll","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"hbr190009r4","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1001\/jama.2011.1880","article-title":"CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.","volume":"306","author":"Holmes","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"hbr190009r5","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel.","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"issue":"8","key":"hbr190009r6","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"issue":"4","key":"hbr190009r7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jacc.2010.05.013","article-title":"ACCF\/AHA clopidogrel clinical alert: approaches to the FDA \u201cboxed warning\u201d: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons.","volume":"56","author":"Holmes","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"10081","key":"hbr190009r8","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/S0140-6736(17)30751-1","article-title":"Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.","volume":"389","author":"Ohman","year":"2017","journal-title":"Lancet"},{"key":"hbr190009r9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ahj.2016.01.004","article-title":"A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: the design of the GEMINI-ACS-1 phase II study.","volume":"174","author":"Povsic","year":"2016","journal-title":"Am Heart J"},{"issue":"3","key":"hbr190009r10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.","volume":"94","author":"Scott","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"hbr190009r11","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1161\/CIRCOUTCOMES.113.000321","article-title":"Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.","volume":"6","author":"Desai","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"hbr190009r12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jcin.2017.07.022","article-title":"Multisite investigation of outcomes with\u00a0implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention.","volume":"11","author":"Cavallari","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"issue":"10","key":"hbr190009r13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s12471-016-0873-z","article-title":"Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands.","volume":"24","author":"Deiman","year":"2016","journal-title":"Neth Heart J"},{"key":"hbr190009r14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ijcard.2016.09.088","article-title":"Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent.","volume":"225","author":"S\u00e1nchez-Ramos","year":"2016","journal-title":"Int J Cardiol"},{"issue":"17","key":"hbr190009r15","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/j.jacc.2018.02.029","article-title":"Pharmacogenomic approach to selecting\u00a0antiplatelet therapy in patients with acute coronary syndromes: the PHARMCLO trial.","volume":"71","author":"Notarangelo","year":"2018","journal-title":"J Am Coll Cardiol"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamacardiology\/article-pdf\/4\/7\/680\/17729198\/jamacardiology_povsic_2019_br_190009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T11:02:55Z","timestamp":1563361375000},"score":1,"resource":{"primary":{"URL":"http:\/\/cardiology.jamanetwork.com\/article.aspx?doi=10.1001\/jamacardio.2019.1510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2019.1510","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,1]]}}}